74 related articles for article (PubMed ID: 15197967)
1. [GVHD].
Hirokawa M; Miura I; Sawada K
Nihon Rinsho; 2004 May; 62 Suppl 5():478-81. PubMed ID: 15197967
[No Abstract] [Full Text] [Related]
2. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506.
Woodle ES; Thistlethwaite JR; Haas M; Josephson MA; Newell KA; Bruce DS; Millis JM; Piper JB; Charette JI
Transplant Proc; 1996 Apr; 28(2):998-9. PubMed ID: 8623495
[No Abstract] [Full Text] [Related]
3. Tacrolimus (FK 506) in clinical cardiac transplantation: a five-year experience.
Pham SM; Kormos RL; Kawai A; Murali S; Hattler BG; Demetris AJ; Griffith BP
Transplant Proc; 1996 Apr; 28(2):1002-4. PubMed ID: 8623208
[No Abstract] [Full Text] [Related]
4. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience.
Alloway RR; Russell WC; Gaber LW; Amiri MH; Vera SR; Gaber AO
Transplant Proc; 1996 Apr; 28(2):995-7. PubMed ID: 8623494
[No Abstract] [Full Text] [Related]
5. Muromonab-CD3 (Orthoclone OKT3), methylprednisolone and cyclosporine for acute graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation.
Benekli M; Hahn T; Williams BT; Cooper M; Roy HN; Wallace P; Stewart C; Bambach B; McCarthy PL
Bone Marrow Transplant; 2006 Sep; 38(5):365-70. PubMed ID: 16862164
[TBL] [Abstract][Full Text] [Related]
6. Early steroid-resistant rejection following orthotopic liver transplantation: new aspects of treatment with FK 506 instead of OKT3?
Dé P; Bechstein WO; Blumhardt G; Lange D; Schattenfroh N; Neuhaus P
Transplant Proc; 1993 Aug; 25(4):2693-4. PubMed ID: 7689279
[No Abstract] [Full Text] [Related]
7. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation.
Weisdorf D; Filipovich A; McGlave P; Ramsay N; Kersey J; Miller W; Blazar B
Bone Marrow Transplant; 1993 Nov; 12(5):531-6. PubMed ID: 8298565
[TBL] [Abstract][Full Text] [Related]
8. Incidence and outcome of OKT3 treatment for early steroid-resistant rejection following hepatic transplantation.
Lange D; Bechstein WO; Blumhardt G; Lemmens P; Schattenfroh N; Neuhaus P
Transplant Proc; 1993 Apr; 25(2):1870-1. PubMed ID: 8470207
[No Abstract] [Full Text] [Related]
9. Acute graft-versus-host disease in thalassaemic marrow transplantation with low-dose antithymocyte globulin.
Khojasteh HN; Zakerinia M; Ramzi M; Haghshenas M
East Mediterr Health J; 1999 May; 5(3):465-9. PubMed ID: 10793825
[TBL] [Abstract][Full Text] [Related]
10. [Chronic graft-versus-host disease].
Chuhjo T; Shiobara S
Nihon Rinsho; 2005 May; 63 Suppl 5():473-8. PubMed ID: 15954394
[No Abstract] [Full Text] [Related]
11. Cyclosporin, methotrexate and prednisolone for graft-versus-host disease prophylaxis in allogeneic peripheral blood progenitor cell transplants.
Hoyt R; Ritchie DS; Roberts AW; Macgregor L; Curtis DJ; Szer J; Grigg AP
Bone Marrow Transplant; 2008 Apr; 41(7):651-8. PubMed ID: 18176619
[TBL] [Abstract][Full Text] [Related]
12. Triple drug maintenance therapy in renal transplantation.
Pallardó LM; Sánchez J; Hernandez M; Górriz JL; Sánchez P; Beneyto I; Rochera A
Transplant Proc; 1992 Feb; 24(1):58-9. PubMed ID: 1539343
[No Abstract] [Full Text] [Related]
13. Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function.
Sumrani N; Hong JH; DiBenedetto A; Clayton R; Miles AM; Markell MS; Distant DA; Fleishhacker J; Sommer BG
Transplant Proc; 1996 Feb; 28(1):400-1. PubMed ID: 8644289
[No Abstract] [Full Text] [Related]
14. Adjuncts to triple-drug therapy after cardiac transplantation: a comparison of Nashville rabbit antithymocyte serum to OKT3.
Aziz S; Kruse AP; Roby PV; Allen MD; Khan K; Fishbein D
Transplant Proc; 1994 Oct; 26(5):2721-3. PubMed ID: 7940852
[No Abstract] [Full Text] [Related]
15. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
Schwinghammer TL; Bloom EJ
Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255
[TBL] [Abstract][Full Text] [Related]
16. OKT3 first-line treatment of acute rejection episodes following combined pancreas and kidney transplantation.
Cantarovich D; Hourmant M; Dantal J; Giral M; Paineau J; Karam G; Soulillou JP
Transplant Proc; 1994 Apr; 26(2):549. PubMed ID: 8171548
[No Abstract] [Full Text] [Related]
17. Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies.
Hebart H; Ehninger G; Schmidt H; Berner B; Reuss-Borst M; Waller HD; Müller CA; Einsele H
Bone Marrow Transplant; 1995 Jun; 15(6):891-4. PubMed ID: 7581087
[TBL] [Abstract][Full Text] [Related]
18. Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia.
Nordlander A; Mattsson J; Ringdén O; Leblanc K; Gustafsson B; Ljungman P; Svenberg P; Svennilson J; Remberger M
Biol Blood Marrow Transplant; 2004 Mar; 10(3):195-203. PubMed ID: 14993885
[TBL] [Abstract][Full Text] [Related]
19. Outcome of monoclonal antibody induction and anti-rejection therapy in pancreas transplantation.
Bruce DS; Newell KA; Woodle ES; Millis JM; Piper JB; Huss E; Thistlethwaite JR
Transplant Proc; 1996 Aug; 28(4):2136-7. PubMed ID: 8769180
[No Abstract] [Full Text] [Related]
20. Tacrolimus/Methotrexate versus cyclosporine/methotrexate as graft-versus-host disease prophylaxis in patients with severe aplastic anemia who received bone marrow transplantation from unrelated donors: results of matched pair analysis.
Yagasaki H; Kojima S; Yabe H; Kato K; Kigasawa H; Sakamaki H; Tsuchida M; Kato S; Kawase T; Muramatsu H; Morishima Y; Kodera Y
Biol Blood Marrow Transplant; 2009 Dec; 15(12):1603-8. PubMed ID: 19896085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
